BGNE BeiGene
- 161.640
- -0.370-0.23%
BeiGene News
BeiGene (06160.HK) issued 155,900 shares due to restricted share units
On May 2, GLONGHUI (06160.HK) issued an announcement. On April 30, 2024, 155,900 common shares will be issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene (06160) issued 261.82 million shares under the share award scheme on April 30
According to the Zhitong Finance App, BeiGene (06160) announced that 261.82 million shares will be issued under the share award program on April 30, 2024.
BeiGene PD-1 inhibitor Baizean approved 13th application for indication in China
China National Drug Administration (NMPA) approves Baize'an (tirelizumab) as a new indication for gastric cancer, Beijing, April 30, 2024/4/2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235), a global cancer treatment innovation company, announced today that its PD-1 inhibitor baizean (tirelizumab) has been officially approved by China's National Drug Administration (China Drug Administration) in combination with fluorouracil and platinum chemotherapeutics For advanced local use, unresectable or metastatic stomach or stomach eating
BeiGene issued approximately 238,600 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 29, 2024, approximately 238,600 shares were issued due to the ownership of restricted share units granted under the equity plan.
BeiGene (06160.HK) issued 238,600 shares due to restricted share units
On April 30, GLONGHUI | BeiGene (06160.HK) issued an announcement. On April 29, 2024, 238,600 common shares were issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene issued approximately 121,000 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 28, 2024, approximately 121,000 shares were issued due to the ownership of restricted share units granted under the equity plan.
BeiGene (06160) issued approximately 121,000 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 28, 2024, due to a restricted share list granted under an equity plan...
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio?Vertiv Holdings Co (NYSE:VRT) increased 23.3% after it reported bet
US MOVERS&SHAKERS Apr 22-Apr 26, 2024
Here are the top 10 gainers and losers of the week.
BeiGene (NASDAQ:BGNE) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
BeiGene reports 2023 annual results, with revenue surging 82.13% to 17.423 billion yuan
According to the Zhitong Finance App, BeiGene (688235.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 17.423 billion yuan, a year-on-year increase of 82.13%; net loss attributable to shareholders of listed companies narrowed sharply to 6.716 billion yuan. Baiyueze, a BTK inhibitor independently developed by the company, has been approved for multiple indications in 70 markets including the United States, China, the European Union, the United Kingdom, Canada, Australia, South Korea and Switzerland. It has established an extensive clinical development layout around the world, and has enrolled more than 5,000 subjects in 29 countries and regions. Momoetsusawa
BeiGene Releases “2023 Responsible Business and Sustainability” Report, Announces Global Progress
The 2023 annual report details the company's achievements in sustainability and future plans in Beijing, China; Cambridge, MA; and Basel, Switzerland, April 26, 2024/PRNewswire/ -- BeiGene, Ltd. (NASDAQ: BGNE; Hong Kong Stock Exchange: 06160; Shanghai Stock Exchange: 688235), a global oncology innovation company, today released the “2023 Responsible Business and Sustainability” report, which highlights the company's strategy, progress made with current goals, and how to achieve more in the future Positive new goals. In the report
百濟神州：2023年度報告
Express News | Beigene : Bernstein Cuts Target Price to $152 From $161
BeiGene (BGNE) Receives a Hold From Bernstein
Global Oncology Innovator BeiGene Highlights New Data Across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
Evaluating BeiGene: Insights From 6 Financial Analysts
In the last three months, 6 analysts have published ratings on BeiGene (NASDAQ:BGNE), offering a diverse range of perspectives from bullish to bearish.The following table provides a quick overview of
BeiGene Is Maintained at Buy by TD Cowen
BeiGene Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on BeiGene, Raises Price Target to $236
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 64.52% TD Cowen $235 → $236 Maintains Buy 04/08/2024 14.53% B of A Securities $179.3 → $164.3 M
Analysis
Price Target
No Data
